Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669286 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL668644 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11882735 | 0.84 | LMNA (0.35) | LMNAL3MBTL1TDP1 | |
| SCHEMBL3501009 | 0.70 | ALDH1A1 (0.42) | LMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL23066399 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2477078 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2297640 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594082 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20567656 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL763 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102370967-A | Novel application of IL-1Ra (interleukin-1 receptor antagonist) and tumor treatment medicinal composition kit thereof | UNIV SHANGHAI JIAOTONG | 2012-03-14 | — | — | CN | claimed |
| US-8124051-B2 | Peptide, oligonucleotide suppressor of antiapoptotic cellular defense and anti-tumor agent covalently attached to same carrier peptide via bi-functional water-soluble polymer, so there is simultaneous uptake of suppressor and anti-tumor agent by tumor cells | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-02-28 | — | — | US | claimed |
| US-11896713-B2 | Strategies to enhance lung cancer treatment | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220125728-A1 | Strategies to Enhance Lung Cancer Treatment | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3329917-B1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO CO LTD (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10434091-B2 | Agent for treating and/or preventing adult T cell leukemia/lymphoma | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20180200238-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3329917-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-06 | — | — | EP | disclosed |
| CN-102834113-A | Pharmaceutical composition for treating and/or preventing cancer | TORAY INDUSTRIES | 2012-12-19 | — | — | CN | disclosed |
| CN-102822198-A | CTLA4 protein and uses thereof | ABBOTT BIOTHERAPEUTICS CORP | 2012-12-12 | — | — | CN | disclosed |
| CN-102822335-A | Pharmaceutical composition for treatment and/or prevention of cancer | TORAY INDUSTRIES | 2012-12-12 | — | — | CN | disclosed |
| CN-102821789-A | Pharmaceutical composition for treatment and/or prevention of cancer | TORAY INDUSTRIES | 2012-12-12 | — | — | CN | disclosed |
| CN-102822199-A | Medicinal composition for treating and/or preventing cancer | TORAY INDUSTRIES | 2012-12-12 | — | — | CN | disclosed |
| CN-102821788-A | Pharmaceutical composition for treatment and/or prevention of cancer | TORAY INDUSTRIES | 2012-12-12 | — | — | CN | disclosed |
| CN-102791735-A | Monoclonal antibodies against progastrin and uses thereof | BIOREALITES S A S | 2012-11-21 | — | — | CN | disclosed |
| CN-102482349-A | Anti-VEGF antibodies and uses thereof | ABBOTT BIOTHERAPEUTICS CORP | 2012-05-30 | — | — | CN | disclosed |
| CN-102439040-A | anti-TNF-alpha antibodies and uses thereof | FACET BIOTECH CORP | 2012-05-02 | — | — | CN | disclosed |
| CN-102370967-A | Novel application of IL-1Ra (interleukin-1 receptor antagonist) and tumor treatment medicinal composition kit thereof | UNIV SHANGHAI JIAOTONG | 2012-03-14 | — | — | CN | disclosed |
| CN-102307570-A | Porous structures with modified biodegradation kinetics | UNIV TEXAS | 2012-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434091-B2 | Agent for treating and/or preventing adult T cell leukemia/lymphoma | MALT1, BCL9, BCL6 | LMNA 1166/4885L3MBTL1 1466/4885TDP1 731/4885 |
| US-20180200238-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | MALT1, BCL9, BCL6 | LMNA 1368/4885L3MBTL1 1178/4885TDP1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.